Myelodysplastic Syndromes News and Research

RSS

Common drug for autoimmune disease may increase risk of myeloid neoplasms

Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms.

3 Feb 2017

Researchers design antibody that recognizes and destroys blood cancer stem cells

A protein-sugar molecule, CD99, occurs more frequently than normal on stem cells responsible for blood cancers, including acute myeloid leukemia (AML) and the related myelodysplastic syndromes.

25 Jan 2017

$Combination treatment produces better outcomes in erythropoietin-refractory MDS patients, study shows$

Combination treatment produces better outcomes in erythropoietin-refractory MDS patients, study shows

Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia.

4 Dec 2016

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

The National Institutes of Health National Heart, Lung and Blood Institute has awarded a $2.4 million grant over four years to Cleveland Clinic cancer researchers Jaroslaw Maciejewski, M.D., and Richard Padgett, Ph.D., to test the hypothesis that alterations in the pattern of splicing of target genes play a major role in the establishment or progression of myelodysplastic syndromes (MDS).

14 Oct 2016

The National MDS Study aims to identify causes, genetic makeup of fatal blood diseases

The National Myelodysplastic Syndromes Natural History Study is underway, the ECOG-ACRIN Cancer Research Group and its collaborators announced today.

26 May 2016

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

In humans the differentiation of stem cells into hundreds of specialized cell types is vital. Differentiation drives development from fertilized egg to a newborn, and it underlies the continuous replacement of the 5 billion cells that die every hour in an adult. On the downside, mutations in differentiation pathways of different cell types can be drivers of cancers.

13 Jan 2016

McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers have taken a giant leap in identifying the early stages of a deadly cancer and predicting how it will develop in individuals.

11 Jan 2016

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.

28 Dec 2015

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.

13 Nov 2015

UCSD researchers suggest that cancer-related mutations common in patients with low blood counts

Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood.

4 Nov 2015

Self-reported fatigue predicts myelodysplastic syndromes survival

Patient-reported fatigue severity is an independent prognostic marker for survival in patients with newly diagnosed intermediate-2- or high-risk myelodysplastic syndromes, according to research published in The Lancet Oncology.

1 Oct 2015

Researchers identify druggable target to potentially root out colon cancer, end relapse

Researchers targeting colorectal cancer stem cells - the root cause of disease, resistance to treatment and relapse - have discovered a mechanism to mimic a virus and potentially trigger an immune response to fight the cancer like an infection.

28 Aug 2015

Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients

Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement.

2 Jul 2015

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment for a range of cancers, researchers at the University of Birmingham have found.

15 May 2015

MD Anderson researchers discover link between telomere degeneration and MDS

A study revealing fresh insight about chromosome "tails" called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes (MDS).

12 May 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Moffitt announces development of innovative investigational biologic agent for MDS

In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases.

18 Nov 2014

Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

For patients with aggressive types of leukemia and other blood cancers, quickly identifying and starting the right treatment can make all the difference.

13 Nov 2014